trial · primary record
ART5803
Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2028-05-30 |
| Primary endpoint | To assess the safety and tolerability of ART5803 |
| Registry ID | NCT07093333 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:10.198Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07093333
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.